Follicular Lymphoma
Conditions
Keywords
Non-Hodgkin's Lymphoma, Follicular Non-Hodgkin's Lymphoma, Lymphoma
Brief summary
The purpose of this study is to determine what dose of bortezomib in combination with tositumomab I-131 is tolerable whether bortezomib and Tositumomab I-131 are effective in the treatment of relapsed or refractory non-hodgkin's lymphoma (NHL). Both agents are effective in treating relapsed and refractory NHL. Administer of the agents together may sensitize the cells to the radiation from Tositumomab I-131.
Interventions
DRUGBortezomib and Tositumomab I-131
Sponsors
GlaxoSmithKline
Millennium Pharmaceuticals, Inc.
Rush University Medical Center
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Previously treated or relapsed follicular lymphoma. One prior therapy required. * Bi-dimensionally measurable disease with at least one lesion measuring \> 2.0 X 2.0cm by CT scan or evaluable disease. * CD20+ at time of diagnosis or subsequently. * Platelet count \> 100,000/uL, ANC \> 1000/uL. * Transaminases less than two-fold normal range. * Adequate renal function defined as \<1.5 X upper limit of normal * HAMA negative * ECOG performance status 0, 1, 2. * Female subject is either post-menopausal or surgically sterilized or willing to use an acceptable method of birth control (i.e., a hormonal contraceptive, intra-uterine device, diaphragm with spermicide, condom with spermicide, or abstinence) for the duration of the study. * Male subject agrees to use an acceptable method for contraception for the duration of the study. * Negative Hepatitis profile screening
Exclusion criteria
* Myocardial infarction within 6 months prior to enrollment or has New York Heart Association (NYHA) Class III or IV heart failure (see section 8.4), uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities. Prior to study entry, any ECG abnormality at Screening has to be documented by the investigator as not medically relevant. * Patient has hypersensitivity to boron or mannitol. * Greater than 25% of the intratrabecular marrow space involved by lymphoma in bone marrow biopsy specimens * Hypocellular bone marrow (≤15% cellularity or marked reduction in bone marrow precursors). * Prior myeloablative therapy. * History of failed stem cell collection. * Prior radiotherapy to fields encompassing more than 25% of the blood-forming marrow. * Prior chemotherapy, biologic therapy, radiation therapy or steroid therapy for NHL within three weeks prior to screening procedures. Six weeks for nitrosureas. Subjects receiving low doses of steroids for non-neoplastic indications may enter the study (low dose steroids is defined as ≤10 mg of prednisone or equivalent per day). * Prior Radioimmunotherapy or bortezomib. * Prior malignancy other than lymphoma, except for adequately treated basal cell or squamous cell skin cancer, in situ uterine cervical cancer, or other cancer for which the subject has been disease-free for five years. * Evidence of active infection requiring intravenous antibiotics at the time of study enrollment. * Known HIV infection. * Known brain or leptomeningeal metastases. * Active obstructive hydronephrosis. * Known Type I hypersensitivity or anaphylactic reactions to murine proteins or any component of the Iodine I 131 tositumomab therapeutic regimen. * Female subject is pregnant or breast-feeding. Confirmation that the subject is not pregnant must be established by a negative serum pregnancy test result obtained during screening. Pregnancy testing is not required for post-menopausal or surgically sterilized women. * Patient has received other investigational drugs with 14 days before enrollment * Serious medical or psychiatric illness likely to interfere with participation in this clinical study. * Patient has Grade 2 peripheral neuropathy within 14 days before enrollment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The Primary Objective of This Study is to Determine the Maximum Tolerated Dose (up to 1.6 mg/m2) of Bortezomib Combined With Tositumomab and Iodine I 131 Tositumomab | Study terminated. |
Secondary
| Measure | Time frame |
|---|---|
| To Further Explore the Toxicity and Efficacy of Bortezomib Combined With Tositumomab and Iodine I 131 Tositumomab and Assess the Tolerability of Bortezomib After Tositumomab | Study Terminated. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Bortezomib in Combination With Tositumomab | 0 |
| Total | 0 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Withdrawal by Subject | 1 |
Baseline characteristics
| Characteristic | — |
|---|---|
| Region of Enrollment United States | — participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 0 / 1 |
| other Total, other adverse events | 0 / 1 |
| serious Total, serious adverse events | 0 / 1 |
Outcome results
Primary
The Primary Objective of This Study is to Determine the Maximum Tolerated Dose (up to 1.6 mg/m2) of Bortezomib Combined With Tositumomab and Iodine I 131 Tositumomab
Time frame: Study terminated.
Population: Subject withdrew
Secondary
To Further Explore the Toxicity and Efficacy of Bortezomib Combined With Tositumomab and Iodine I 131 Tositumomab and Assess the Tolerability of Bortezomib After Tositumomab
Time frame: Study Terminated.
Population: Subject withdrew